SLU-PP-332 is a synthetic small molecule developed by researchers at Saint Louis University as a selective agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ).
🔬 Studied for: Exercise-Mimetic Research
💊 Also studied for: Metabolic-Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
SLU-PP-332 is a synthetic small molecule developed by researchers at Saint Louis University as a selective agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ). It is a comparatively new research compound, first described in the scientific literature in 2023.
SLU-PP-332 activates estrogen-related receptors, transcription factors that regulate genes involved in mitochondrial biogenesis and oxidative metabolism, independent of estrogen receptor signaling itself — a mechanism researchers have compared to the metabolic effects of endurance exercise.
These are effects SLU-PP-332 has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
The original 2023 study describing SLU-PP-332 found that treated mice showed increased running endurance and mitochondrial gene expression without additional exercise, which is why it is frequently described in the research community as an exercise-mimetic candidate.
Beyond endurance, SLU-PP-332 is studied for its effects on fat oxidation and metabolic rate in animal models, an area of interest given ERR's established role in regulating mitochondrial and metabolic gene networks.
Doses used in the foundational mouse studies are documented in that specific research and do not translate to an established human dose. No human dosage of any kind has been clinically evaluated for SLU-PP-332.
Compound X does not provide dosing recommendations. SLU-PP-332 is sold for laboratory research use only and is not intended for human consumption.
SLU-PP-332 is an early-stage research compound with a very limited published safety record, restricted almost entirely to the original mouse studies. It has not been evaluated in humans, is not FDA-approved, and comprehensive toxicology and long-term safety data does not exist.
No. SLU-PP-332 is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Exercise-Mimetic Research — The original 2023 study describing SLU-PP-332 found that treated mice showed increased running endurance and mitochondrial gene expression without additional exercise, which is why it is frequently described in the research community as an exercise-mimetic candidate.
In the US, UK, Canada and Australia, SLU-PP-332 is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
SLU-PP-332 research is indexed on PubMed under search terms such as "SLU-PP-332 ERR agonist" and "estrogen related receptor exercise mimetic."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.